Bristol Myers: Positive Topline Results from Phase 3 Evaluating Mavacamten in Obstructive Hypertrophic Cardiomyopathy

 Bristol Myers Squibb (NYSE: BMY) today announced that VALOR-HCM, the Phase 3 randomized, double-blind, placebo-controlled study evaluating mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM) who are eligible for septal reduction therapy (SRT), met its primary endpoint at Week 16. The safety of mavacamten was consistent with previous studies.

"We are encouraged by the findings from this important study, which add to the growing body of clinical evidence that supports the promise of mavacamten for patients living with obstructive HCM," said Roland Chen, M.D., Senior Vice President, Cardiovascular Development at Bristol Myers Squibb. "We look forward to sharing the results from VALOR-HCM at the American College of Cardiology 71st Annual Scientific Session & Expo taking place in April."

The company plans to share these data with regulatory authorities. Bristol Myers Squibb thanks the patients and investigators participating in the VALOR-HCM clinical trial.

https://finance.yahoo.com/news/bristol-myers-squibb-announces-positive-115900894.html